title: Drugs for rare diseases: influence of orphan designation status on price.
abstract: The literature indicates that the expenditure on orphan drugs will be increasing over the coming years. The market for orphan drugs has inherent market characteristics that sometimes result in high prices. The aim of this study was to analyse whether awarding orphan designation status has an influence on the price setting of drugs for rare disease indications. To this effect, prices of designated orphan drugs were compared with other non-designated drugs for rare disease indications. We identified 28 designated orphan drugs and 16 comparable non-designated drugs for rare disease indications for which we collected official hospital prices (per defined daily dose) in Belgium in 2010. Orphan-designated drugs had a higher median price (138.56 Euros [interquartile range; IQR 406.57 Euros]) than non-designated drugs (16.55 Euros [IQR 28.05 Euros]) for rare disease indications (p < 0.01). In conclusion, our results suggest that awarding orphan designation status in itself is associated with higher prices for drugs for rare disease indications. In order to gain full insight into orphan drug pricing mechanisms, future research should focus on collecting information about the different factors influencing orphan drug pricing.
authors.affiliation: Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium. eline.picavet@pharm.kuleuven.be
authors.forename: Eline
authors.initials: E
authors.lastname: Picavet
authors.forename: Marc
authors.initials: M
authors.lastname: Dooms
authors.forename: David
authors.initials: D
authors.lastname: Cassiman
authors.forename: Steven
authors.initials: S
authors.lastname: Simoens
mesh_terms: D001530:Belgium; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics; D011306:Prescription Fees / Q000706:statistics & numerical data; D035583:Rare Diseases / Q000188:drug therapy* / Q000191:economics